Collection Risk on Long-Term Loans to Argos Therapeutics
First written in FY2017. 4 of 8 entries say "Mitigated", first in FY2019. Latest entry: 2026-05-13.
The whole theme swung hardest in 2023: 8 of 31 companies on the "Worse" side.
10 other companies' latest entry also says "Mitigated".
- 2026-05-13MitigatedOccurring Fact
「During the interim accounting period (1 October 2025 to 31 March 2026), we recovered part of the long-term loans receivable for which an allowance for doubtful accounts had been recognized, and recorded a reversal of the allowance for doubtful accounts of ¥2 million as non-operating income.」
The partial recovery of long-term loans receivable for which an allowance for doubtful accounts had been recognized, and the recording of the reversal, indicate a partial improvement in recovery risk. - FY2020-Q3MitigatedAnnual report
「During the third quarter accounting period, ¥6 million was reversed following the partial collection of long-term loans for which a provision for doubtful accounts had been recorded. As a result, a cumulative ¥18 million reversal of the provision for doubtful accounts was recognized as non-operating income.」
Partial collections progressed on long-term loans to Argos and others for which provisions for doubtful accounts had been recorded, resulting in a cumulative reversal of ¥18 million. - FY2020-Q1MitigatedAnnual report
「A ¥6 million reversal of the provision for doubtful accounts, resulting from the partial collection of long-term loans for which a provision had been recorded, was recognized as non-operating income.」
A ¥6 million reversal was recorded following the partial collection of long-term loans for which a provision for doubtful accounts had been recorded. - FY2019MitigatedAnnual report
「In September 2019, Argos obtained approval of a liquidation plan from the US Bankruptcy Court, and ¥139 million of our bankruptcy and rehabilitation claims and other receivables from Argos included in the plan were repaid under the agreement incorporated into that plan.」
With respect to receivables from Argos for which a full provision for doubtful accounts had been recorded, ¥139 million was repaid, representing a partial improvement in recoveries. - FY2019-Q2WorsenedAnnual report
「The license agreement with Argos Therapeutics, Inc. for the cell therapy product AGS-003 ended on 7 January 2019 because Argos filed for relief under Chapter 11 of the U.S. Bankruptcy Code with the U.S. Bankruptcy Court on 30 November 2018, and the court approved Argos's application to reject the license agreement.」
The disclosure states that Argos filed for commencement of bankruptcy proceedings and that the license agreement was terminated, indicating a further deterioration in the collection risk relating to the long-term loans and other receivables from Argos. - FY2018-Q3WorsenedAnnual report
「Because Argos discontinued development of the licensed product, we abandoned its commercialization. Having determined that concerns had arisen regarding the recoverability of the long-term loans and accrued interest owed by Argos, we recorded an expense of US$4.901 million (¥541.800 million) for the provision for doubtful accounts as an extraordinary loss in the cumulative consolidated period through the third quarter.」
For the long-term loans and other receivables from Argos, the expense for the provision for doubtful accounts increased from ¥520.871 million in Q2 to ¥541.800 million. - FY2018-Q2MaterialisedAnnual report
「Having determined that concerns had arisen regarding the recoverability of the long-term loans and accrued interest owed by Argos, we recorded an expense of US$4.901 million (¥520.871 million) for the provision for doubtful accounts as an extraordinary loss in the cumulative consolidated period through the second quarter.」
Following Argos's discontinuation of development, concerns over the recovery of the long-term loans and other receivables materialized, and an expense of ¥520.871 million for the provision for doubtful accounts was recorded. - FY2017First statedAnnual report
「The Group has provided a long-term loan to Argos Therapeutics, Inc. of the United States, the counterparty to the license agreement for this business. Because the balance was US$4 million (¥450,960 thousand) as of 30 September 2017, if Argos’s operations do not proceed as planned and an allowance or similar provision is required, this could affect the Group’s performance.」
The Company disclosed collection and provisioning risk relating to a ¥450,960 thousand long-term loan to Argos, the licensee for AGS-003.